These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36323666)

  • 1. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.
    Voigt EA; Gerhardt A; Hanson D; Jennewein MF; Battisti P; Reed S; Singh J; Mohamath R; Bakken J; Beaver S; Press C; Soon-Shiong P; Paddon CJ; Fox CB; Casper C
    NPJ Vaccines; 2022 Nov; 7(1):136. PubMed ID: 36323666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery.
    Gerhardt A; Voigt E; Archer M; Reed S; Larson E; Van Hoeven N; Kramer R; Fox C; Casper C
    Mol Ther Methods Clin Dev; 2022 Jun; 25():205-214. PubMed ID: 35308783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.
    Rice A; Verma M; Voigt E; Battisti P; Beaver S; Reed S; Dinkins K; Mody S; Zakin L; Tanaka S; Morimoto B; Olson CA; Gabitzsch E; Safrit JT; Spilman P; Casper C; Soon-Shiong P
    Front Immunol; 2022; 13():910136. PubMed ID: 35911728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines.
    Duhen R; Beymer M; Jensen SM; Abbina S; Abraham S; Jain N; Thomas A; Geall AJ; Hu HM; Fox BA; Weinberg AD
    Front Immunol; 2022; 13():896310. PubMed ID: 36238275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19.
    Silva-Pilipich N; Beloki U; Salaberry L; Smerdou C
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
    Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
    Front Immunol; 2022; 13():858904. PubMed ID: 35592324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine.
    Komori M; Morey AL; Quiñones-Molina AA; Fofana J; Romero L; Peters E; Matsuda K; Gummuluru S; Smith JF; Akahata W; Akiyama H
    bioRxiv; 2023 Nov; ():. PubMed ID: 37961509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.
    Chen X; Wang W; Chen X; Wu Q; Sun R; Ge S; Zheng N; Lu W; Yang J; Rodewald L; Yu H
    BMC Med; 2022 Jan; 20(1):36. PubMed ID: 35086547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines.
    Blakney AK; McKay PF; Hu K; Samnuan K; Jain N; Brown A; Thomas A; Rogers P; Polra K; Sallah H; Yeow J; Zhu Y; Stevens MM; Geall A; Shattock RJ
    J Control Release; 2021 Oct; 338():201-210. PubMed ID: 34418521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines.
    Tregoning JS; Stirling DC; Wang Z; Flight KE; Brown JC; Blakney AK; McKay PF; Cunliffe RF; Murugaiah V; Fox CB; Beattie M; Tam YK; Johansson C; Shattock RJ
    Mol Ther Nucleic Acids; 2023 Mar; 31():29-42. PubMed ID: 36589712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
    McKay PF; Hu K; Blakney AK; Samnuan K; Brown JC; Penn R; Zhou J; Bouton CR; Rogers P; Polra K; Lin PJC; Barbosa C; Tam YK; Barclay WS; Shattock RJ
    Nat Commun; 2020 Jul; 11(1):3523. PubMed ID: 32647131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyplex nanomicelle delivery of self-amplifying RNA vaccine.
    Chang YH; Lin MW; Chien MC; Ke GM; Wu IE; Lin RL; Lin CY; Hu YC
    J Control Release; 2021 Oct; 338():694-704. PubMed ID: 34509585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines.
    Hvidt AK; Baerends EAM; Søgaard OS; Stærke NB; Raben D; Reekie J; Nielsen H; Johansen IS; Wiese L; Benfield TL; Iversen KK; Mustafa AB; Juhl MR; Petersen KT; Ostrowski SR; Lindvig SO; Rasmussen LD; Schleimann MH; Andersen SD; Juhl AK; Dietz LL; Andreasen SR; Lundgren J; Østergaard L; Tolstrup M;
    Front Med (Lausanne); 2022; 9():994160. PubMed ID: 36262278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection.
    Rappaport AR; Hong SJ; Scallan CD; Gitlin L; Akoopie A; Boucher GR; Egorova M; Espinosa JA; Fidanza M; Kachura MA; Shen A; Sivko G; Van Abbema A; Veres RL; Jooss K
    Nat Commun; 2022 Jun; 13(1):3289. PubMed ID: 35672369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets.
    McKay PF; Zhou J; Frise R; Blakney AK; Bouton CR; Wang Z; Hu K; Samnuan K; Brown JC; Kugathasan R; Yeow J; Stevens MM; Barclay WS; Tregoning JS; Shattock RJ
    Oxf Open Immunol; 2022; 3(1):iqac004. PubMed ID: 35996628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.